Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
暂无分享,去创建一个
M. Konopleva | M. Andreeff | K. Bhalla | H. Kantarjian | G. Garcia-Manero | K. Patel | T. Kadia | F. Ravandi | Koichi Takahashi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | N. Pemmaraju | N. Short | S. Loghavi | G. Tang | L. Masarová | K. Sasaki | A. Maiti | S. Venugopal | A. Bidikian | G. Issa | M. Yilmaz | S. Pierce
[1] J. Dipersio,et al. Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101) , 2021, Blood.
[2] M. Andreeff,et al. Therapeutic implications of menin inhibition in acute leukemias , 2021, Leukemia.
[3] Tamara J. Blätte,et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. , 2021, Blood.
[4] M. Konopleva,et al. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. , 2020, Blood cancer discovery.
[5] P. Fenaux,et al. Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2020 .
[6] J. Byrd,et al. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression , 2020, Clinical Cancer Research.
[7] M. Konopleva,et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. , 2020, Blood advances.
[8] S. Saad,et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. , 2020, Blood.
[9] S. Asthana,et al. Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. , 2019, Cancer discovery.
[10] Tamara J. Blätte,et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation , 2019, Nature Communications.
[11] T. Haferlach,et al. NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. , 2018, Blood advances.
[12] J. Jorgensen,et al. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? , 2017, Clinics in laboratory medicine.
[13] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[14] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[15] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[16] Yashma Patel,et al. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[17] R. Majeti,et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.
[18] H. Kantarjian,et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.
[19] Uku. Innere Medizin. Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia , 2014 .
[20] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[21] N. Bolli,et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? , 2011, Blood.
[22] Stefan Fröhling,et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.
[23] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[24] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.